Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
1．Number of Data-submitting Facilities* (745 facilities)≧ 900 beds
N=59

62.7% (37 facilities)

37.3% (22 facilities)

500 - 899 beds
N=351

60.1% (211 facilities)

39.9% (140 facilities)

JANIS
Members†
JANIS Nonmembers‡

28.9% (476 facilities)
200 - 499 beds

71.1% (1,172 facilities)

N=1,648

0.4% (21 facilities)< 200 beds
N=5,436

99.6% (5,415 facilities)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

* Data-submitting Facilities indicate facilities included in Annual Open Report 2013.
† Number of JANIS Members = Number of facilities included in Annual Open Report 2013.
‡ Number of JANIS Non-members = (Number of facilities nationwide in 2012¶)－(Number of facilities
included in Annual Open Report 2013)

Number of beds

Number of facilities nationwide
in 2012¶

Number of Facilities Included in Annual Open Report 2013
(percentage of facilities nationwide)≧ 900 beds

59

37

( 62.7% )500 - 899 beds

351

211

( 60.1% )200 - 499 beds

1,648

476

( 28.9% )< 200 beds

5,436

21

( 0.4% )

-

0

(

7,494

745

Unknown
Total

-

)

( 9.9% )¶ Data of medical facilities is referred to Vital Statistics 2012.
Mental hospitals are excluded.

1
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
2．Number of Data-submitting Facilities,
Specimens and Isolates Counted by Specimen Source

Specimen Source

Number of facilities
included in Annual Open
Report 2013

Number of Specimens

Number of culture-positive
specimens(Number of isolates)

Respiratory

745

1,371,436

872,558(1,836,662)

Urine

742

549,028

290,158(444,885)

Feces

745

375,319

184,759(367,895)

Blood

742

1,344,364

173,214(195,963)

Cerebrospinal fluid

690

58,426

2,807(3,117)

Others745

918,246424,372(746,333)

Total

745

4,616,819

1,947,868(3,594,855)

Inpatient specimens are counted.
All isolated bacteria except Isolated Bacterial Code 9999 (comments only) are counted.
Specimen Source Code： http://www.nih-janis.jp/section/master/specimenentitytype_ver1.0_20070701.xls

2This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
3．Isolated Bacteria from Blood Specimens
Blood Isolates (N=195,963)
05,000 10,000 15,000 20,000 25,000 30,000

Escherichia coli

28,236 (14.4%)

Staphylococcus aureus

27,625 (14.1%)
22,084 (11.3%)

Staphylococcus epidermidis

18,698 (9.5%)

Coagulase-negative staphylococci (CNS)*

12,159 (6.2%)

Klebsiella pneumoniae
Pseudomonas aeruginosa

6,428 (3.3%)

Enterococcus faecalis

6,393 (3.3%)

Enterococcus faecium

4,580 (2.3%)

Enterobacter cloacae

4,385 (2.2%)

Candida albicans

3,950 (2.0%)

Bacillus cereus

3,377 (1.7%)

Bacillus sp.

2,957 (1.5%)

Klebsiella oxytoca

2,952 (1.5%)

Corynebacterium sp.

2,808 (1.4%)

Acinetobacter spp.†

2,267 (1.2%)

Others 47,064 (24.0%)* Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,
Staphylococcus epidermidis).
†Acinetobacter spp. correspond to Isolated Bacterial Codes 4400-4403.

Inpatient specimens are counted.
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 401 (venous blood) and Code 402 (arterial blood) are counted.
Percentage of Corresponding Blood Isolates = (Number of Corresponding Blood Isolates ) / (Total Number ofBlood Isolates ) x 100
Isolated Bacterial Code： http://www.nih-janis.jp/section/master/infectiousagentcode_ver4.1_20121029.xls
Specimen Source Code： http://www.nih-janis.jp/section/master/specimenentitytype_ver1.0_20070701.xls

3This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
3．Isolated Bacteria from Cerebrospinal Fluid Specimens
Cerebrospinal Fluid Isolates (N=3,117)
0

200

400

600

800

598 (19.2%)

Staphylococcus epidermidis

464 (14.9%)

Coagulase-negative staphylococci (CNS)*

410 (13.2%)

Staphylococcus aureus
Corynebacterium sp.

136 (4.4%)

Streptococcus pneumoniae

125 (4.0%)

Cryptococcus neoformans

123 (3.9%)Enterococcus faecalis

107 (3.4%)

Escherichia coli

97 (3.1%)

Propionibacterium acnes

92 (3.0%)

Pseudomonas aeruginosa

83 (2.7%)

Klebsiella pneumoniae

74 (2.4%)

Streptococcus agalactiae

61 (2.0%)

Acinetobacter spp.†

57 (1.8%)

Staphylococcus sp.

50 (1.6%)

Bacillus sp.

41 (1.3%)

Others 599 (19.2%)* Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,
Staphylococcus epidermidis).
†Acinetobacter spp. correspond to Isolated Bacterial Codes 4400-4403.

Inpatient specimens are counted.
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 403 (cerebrospinal fluid) are counted.
Percentage of Corresponding Cerebrospinal Fluid Isolates = (Number of Corresponding Cerebrospinal Fluid
Isolates ) / (Total Number of Cerebrospinal Fluid Isolates ) x 100
Isolated Bacterial Code： http://www.nih-janis.jp/section/master/infectiousagentcode_ver4.1_20121029.xls
Specimen Source Code： http://www.nih-janis.jp/section/master/specimenentitytype_ver1.0_20070701.xls

4This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
4．Number of Patients* and Isolation Rate of Major Bacteria

Number of Patients(Total Isolation Rate‡)
2009
Number of Specimen-submitting

2010

2011

2012

2013

Distribution of
Isolation Rate (%)¶
among Data-submitting Facilities†

1,056,555 cases 1,069,216 cases 1,309,993 cases 1,453,969 cases 1,584,041 cases

Patients

180,184 cases

S. aureus

175,145 cases

210,382 cases

221,239 cases

231,909 cases(17.05%)(16.38%)(16.06%)(15.22%)(14.64%)

S. epidermidis

51,223 cases

47,523 cases

64,588 cases

65,531 cases

69,423 cases(4.85%)(4.44%)(4.93%)(4.51%)(4.38%)

S. pneumoniae

30,222 cases

31,426 cases

32,501 cases

30,484 cases

32,083 cases(2.86%)(2.94%)(2.48%)(2.10%)(2.03%)

E. faecalis

61,113 cases

59,458 cases

75,862 cases

82,510 cases

87,239 cases(5.78%)(5.56%)(5.79%)(5.67%)(5.51%)

E. faecium

18,248 cases

18,674 cases

23,523 cases

26,941 cases

29,540 cases

E. coli

K. pneumoniae

Enterobacter spp.

S. marcescens

P. aeruginosa

Acinetobacter spp.

(1.73%)(1.75%)(1.80%)(1.85%)(1.86%)

116,227 cases

118,958 cases

151,601 cases

171,361 cases

189,127 cases(11.00%)(11.13%)(11.57%)(11.79%)(11.94%)56,924 cases

60,040 cases

77,702 cases

85,532 cases

93,395 cases(5.39%)(5.62%)(5.93%)(5.88%)(5.90%)

39,349 cases

40,363 cases

53,484 cases

57,843 cases

62,966 cases(3.72%)(3.78%)(4.08%)(3.98%)(3.98%)

15,248 cases

15,116 cases

18,762 cases

19,452 cases

20,358 cases(1.44%)(1.41%)(1.43%)(1.34%)(1.29%)

81,437 cases

80,160 cases

99,299 cases

101,821 cases

105,968 cases(7.71%)(7.50%)(7.58%)(7.00%)(6.69%)

16,320 cases

16,107 cases

20,551 cases

20,997 cases

23,447 cases(1.54%)(1.51%)(1.57%)(1.44%)(1.48%)

Inpatient specimens are counted.
* The number of duplicates within 30 days is not recounted for Patients with Major Bacteria and Specimensubmitting Patients (See Appendix).
‡ Total Isolation Rate

= （Total Number of Patients with Major Bacteria for Data-submitting Facilities ) / (Total

Number of Specimen-submitting Patients for Data-submitting Facilities) x 100¶ Isolation Rate = (Number of Patients with Major Bacteria for Each Facility) / (Number of Specimen-submitting
Patients for Each Facility) x 100† Data-submitting Facilities indicate facilities included in Annual Open Report 2013

5This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
5．Number of Patients* and Isolation Rate of Speciﬁc AMR Bacteria

Number of Patients(Total Isolation Rate‡)
2009
Number of Specimen-submitting

2010

2011

2012

2013

Distribution of
Isolation Rate (%)¶
among Data-submitting Facilities†

1,056,555 cases 1,069,216 cases 1,309,993 cases 1,453,969 cases 1,584,041 cases

Patients
Methicillin-resistant
Staphylococcus aureus(MRSA)
Vancomycin-resistant
Staphylococcus aureus(VRSA)
Vancomycin-resistant105,722 cases

100,845 cases

114,933 cases

117,209 cases

118,539 cases(10.01%)(9.43%)(8.77%)(8.06%)(7.48%)

0 cases

0 cases

0 cases

0 cases

0 cases(0.00%)(0.00%)(0.00%)(0.00%)(0.00%)

540 cases

520 cases

407 cases

236 cases

289 cases

Enterococci(VRE)(0.05%)(0.05%)(0.03%)(0.02%)(0.02%)

Penicillin-resistant13,662 cases

14,769 cases

15,062 cases

12,874 cases

12,593 cases

Streptococcus pneumoniae(PRSP)
Multidrug-resistant(1.29%)(1.38%)(1.15%)(0.89%)(0.79%)

1,928 cases

1,872 cases

2,388 cases

2,059 cases

1,822 cases

Pseudomonas aeruginosa(MDRP)(0.18%)(0.18%)(0.18%)(0.14%)(0.12%)

Multidrug-resistant

32 cases

55 cases

115 cases

163 cases

102 cases

Acinetobacter spp.(MDRA)(0.00%)(0.01%)(0.01%)(0.01%)(0.01%)

13,727 cases

13,425 cases

16,479 cases

15,815 cases

15,593 cases(1.30%)(1.26%)(1.26%)(1.09%)(0.98%)

Carbapenem-resistant

172 cases

131 cases

118 cases

76 cases

66 cases

Serratia marcescens(0.02%)(0.01%)(0.01%)(0.01%)(0.00%)

3rd Generation Cephalosporin-

1,875 cases

2,050 cases

3,155 cases

3,419 cases

3,646 cases

resistant Klebsiella pneumoniae(0.18%)(0.19%)(0.24%)(0.24%)(0.23%)

3rd Generation Cephalosporin-

Carbapenem-resistantPseudomonas aeruginosa

7,446 cases

9,196 cases

14,927 cases

18,843 cases

22,212 cases

resistant Escherichia coli

(0.70%)(0.86%)(1.14%)(1.30%)(1.40%)

Fluoroquinolone-resistant19,832 cases

22,996 cases

33,000 cases

41,684 cases

49,466 cases(1.88%)(2.15%)(2.52%)(2.87%)(3.12%)

Escherichia coli

Inpatient specimens with MIC Value reported by either the broth microdilution method or Etest are counted.
* The number of duplicates within 30 days is not recounted for the Patients with Specific AMR Bacteria andSpecimen-submitting Patients (See Appendix).
‡ Total Isolation Rate = (Total Number of Patients with Speciﬁc AMR Bacteria for Data-submitting Facilities) /(Total Number of Specimen-submitting Patients for Data-submitting Facilities) x 100¶ Isolation Rate = (Number of Patients with Specific AMR Bacteria for Each Facility) / (Number of Specimensubmitting Patients for Each Facility) x 100† Data-submitting Facilities indicate facilities included in Annual Open Report 2013

6This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
6．Percentage of Facilities Reporting Speciﬁc AMR Bacteria
Percentage of Facilities Reporting Specific AMR Bacteria in 2013 (N=745)
Facilities reporting at least one corresponding Specific AMR Bacteria
Facilities reporting no corresponding Specific AMR Bacteria
Methicillin-resistant Staphylococcus aureus(MRSA)

745 (100.0%)

Vancomycin-resistant Staphylococcus aureus(VRSA)

745 (100.0%)

Vancomycin-resistant Enterococci(VRE)

64 (8.6%)681 (91.4%)605 (81.2%)

Penicillin-resistant Streptococcus pneumoniae(PRSP)

371 (49.8%)374 (50.2%)

Multidrug-resistant Pseudomonas aeruginosa(MDRP)
Multidrug-resistant Acinetobacter spp.(MDRA)

28 (3.8%)717 (96.2%)
696 (93.4%)

Carbapenem-resistant Pseudomonas aeruginosa
Carbapenem-resistant Serratia marcescens

140 (18.8%)686 (92.1%)

59 (7.9%)229 (30.7%)516 (69.3%)

3rd Generation Cephalosporin-resistant Klebsiella pneumoniae

75 (10.1%)

670 (89.9%)

3rd Generation Cephalosporin-resistant Escherichia coli

38 (5.1%)

707 (94.9%)

Fluoroquinolone-resistant Escherichia coli0%49 (6.6%)

20%

40%

60%

80%

100%

Percentage of Facilities Reporting Specific AMR Bacteria for the Past Five Years
2009
Number of facilities included in Annual Open Report

2010

2011

2012

2013

499

495

594

660

745

100.0%

100.0%

100.0%

100.0%

100.0%

0.0%

0.0%

0.0%

0.0%

0.0%

Vancomycin-resistant Enterococci(VRE)

12.8%

11.9%

11.1%

10.8%

8.6%

Penicillin-resistant Streptococcus pneumoniae(PRSP)

77.2%

78.0%

85.0%

83.8%

81.2%

Multidrug-resistant Pseudomonas aeruginosa(MDRP)

55.9%

58.8%

59.6%

53.2%

50.2%

Multidrug-resistant Acinetobacter spp.(MDRA)

5.2%

4.8%

5.2%

4.4%

3.8%

Carbapenem-resistant Pseudomonas aeruginosa

86.8%

87.9%

94.8%

94.8%

93.4%

Carbapenem-resistant Serratia marcescens

17.2%

14.7%

13.6%

8.8%

7.9%

3rd Generation Cephalosporin-resistant Klebsiella pneumoniae

59.1%

63.2%

69.9%

69.2%

69.3%

3rd Generation Cephalosporin-resistant Escherichia coli

81.2%

83.2%

91.8%

90.0%

89.9%

Fluoroquinolone-resistant Escherichia coli

84.6%

86.9%

94.6%

93.9%

94.9%

Methicillin-resistant Staphylococcus aureus(MRSA)
Vancomycin-resistant Staphylococcus aureus(VRSA)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Percentage of Facilities Reporting Specific AMR Bacteria = (Number of Facilities Reporting at Least one Corresponding Specific
AMR Bacteria) / (Number of Data-submitting Facilities）

7
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (MSSA)†
S : Susceptible

I : Intermediate

33,815 (41.0%)

PCG (N=82,477)

R : Resistant

48,662 (59.0%)
I:74 (0.1%)
93,686 (99.7%)

CEZ (N=93,945)

R:19 (0.2%)

11,211 (99.8%)

CVA/AMPC (N=11,230)

I:23 (0.0%)
88,218 (99.8%)

IPM (N=88,422)

GM (N=90,871)

EM (N=88,528)

I:1,524 (1.7%)
18,362 (20.2%)

65,577 (74.1%)

I:1,700 (1.9%)
21,251 (24.0%)
I:944 (1.1%)
2,658 (3.2%)

80,312 (95.7%)

MINO (N=94,425)

I:383 (0.4%)
93,535 (99.1%)

ST (N=74,763)

R:231 (0.3%)

74,532 (99.7%)

10%

20%

30%

40%

50%

R:507 (0.5%)

I:984 (1.1%)
9,528 (10.6%)

79,129 (88.3%)

0%

R:181 (0.2%)

70,985 (78.1%)

CLDM (N=83,914)

LVFX (N=89,641)

R:185 (0.2%)

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. aureus (MSSA) corresponds to Isolated Bacterial Codes 1304, 1305 and 1306; and also to Isolated Bacterial Code 1301
susceptible to Antimicrobial Code 1208 (Oxacillin).

8This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (MRSA)†S : Susceptible
GM (N=112,173)

47,242 (42.1%)

EM (N=108,607)

I:1,619 (1.5%)
11,016 (10.1%)

I : Intermediate
I:1,924 (1.7%)

63,007 (56.2%)

95,972 (88.4%)

CLDM (N=105,503)

I:1,640 (1.6%)
32,878 (31.2%)

MINO (N=120,300)

57,513 (47.8%)

70,985 (67.3%)
I:18,131 (15.1%)

119,300 (99.9%)

TEIC (N=113,684)

113,663 (100.0%)
I:399 (0.3%)
14,716 (12.8%)

44,656 (37.1%)
I:141 (0.1%)

VCM (N=119,441)

LVFX (N=114,551)

R : Resistant99,436 (86.8%)
R:475 (0.5%)

90,229 (99.5%)

ST (N=90,704)
0%

10%

20%

30%

40%

50%

60%

S : Susceptible

70%

0%

10%

20%

30%

80%

90%

100%

NS : Non-susceptible
NS:37 (0.0%)

85,186 (100.0%)

LZD (N=85,223)

R:5 (0.0%)

I:16 (0.0%)

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. aureus (MRSA) corresponds to Isolated Bacterial Codes 1303, and also to Isolated Bacterial Code 1301 Resistant to
Antimicrobial Code 1208 (Oxacillin).

9This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus epidermidis†
S : Susceptible

PCG (N=55,087)

I : Intermediate

R : Resistant49,363 (89.6%)

5,724 (10.4%)

43,263 (79.9%)

MPIPC (N=54,148) 10,885 (20.1%)

I:19 (0.0%)

R:4 (0.0%)64,364 (100.0%)

VCM (N=64,387)

I:2,469 (4.0%)

R:309 (0.5%)

58,374 (95.5%)

TEIC (N=61,152)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. epidermidis corresponds to Isolated Bacterial Code 1312.

10This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Coagulase-negative staphylococci (CNS)†
S : Susceptible

PCG (N=42,033)

I : Intermediate

34,428 (81.9%)

7,605 (18.1%)

31,308 (72.7%)

11,745 (27.3%)

MPIPC (N=43,053)

R : Resistant

I:31 (0.1%)

R:29 (0.1%)

52,057 (99.9%)

VCM (N=52,117)

I:957 (2.0%)

R:469 (1.0%)

46,386 (97.0%)

TEIC (N=47,812)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
† Coagulase-negative staphylococci (CNS) corresponds to Isolated Bacterial Codes 1311 and 1313-1325 (except Code1312:Staphylococcus epidermidis).

11
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterococcus faecalis†
S : Susceptible

I : Intermediate

R : Resistant
R:1,152 (1.8%)

PCG (N=65,220)

64,068 (98.2%)

R:211 (0.3%)
ABPC (N=72,587)

EM (N=64,465)

72,376 (99.7%)

16,478 (25.6%)
11,177 (17.3%)

MINO (N=74,880)

22,394 (29.9%)

36,810 (57.1%)

16,798 (22.4%)

35,688 (47.7%)

I:15 (0.0%)

R:33 (0.0%)

I:4 (0.0%)

R:9 (0.0%)75,114 (99.9%)

VCM (N=75,162)

TEIC (N=69,500)

69,487 (100.0%)

I:743 (1.0%)
11,013 (15.5%)

59,139 (83.4%)

LVFX (N=70,895)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†E. faecalis corresponds to Isolated Bacterial Codes 1201 and 1202.

12This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterococcus faecium†
S : Susceptible

I : Intermediate

R : Resistant

PCG (N=23,466)

2,889 (12.3%)

20,577 (87.7%)

ABPC (N=26,199)

3,442 (13.1%)

22,757 (86.9%)

S:1,473 (6.2%) I:1,855 (7.9%)
EM (N=23,594)

20,266 (85.9%)

11,871 (41.8%)

MINO (N=28,387)

8,200 (28.9%)

8,316 (29.3%)

I:209 (0.7%)

R:198 (0.7%)

27,927 (98.6%)

VCM (N=28,334)

I:5 (0.0%)

R:62 (0.2%)

26,215 (99.7%)

TEIC (N=26,282)

I:831 (3.2%)
LVFX (N=25,629)

3,150 (12.3%)

21,648 (84.5%)

I:143 (0.8%)

R:5 (0.0%)

18,413 (99.2%)

LZD (N=18,561)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†E. faecium corresponds to Isolated Bacterial Codes 1205 and 1206.

13
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae†
S : Susceptible

I : Intermediate

14,331 (52.5%)

PCG (N=27,315)

9,638 (35.3%)3,346 (12.2%)

22,185 (95.8%)

CTX (N=23,147)

R : Resistant

I:507 (2.2%)

I:3,308 (13.2%)
1,281 (5.1%)

20,454 (81.7%)

MEPM (N=25,043)
I:620 (2.8%)
2,489 (11.1%)

EM (N=22,483)

8,252 (41.8%)

CLDM (N=19,759)

19,374 (86.2%)
I:410 (2.1%)

11,097 (56.2%)
I:161 (0.6%)794 (3.1%)

24,866 (96.3%)

LVFX (N=25,821)

0%

10%

20%

R:455 (2.0%)

30%

40%

50%

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
25,477 (100.0%)

VCM (N=25,477)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.

14This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(CLSI2007)(Cerebrospinal Fluid)†
S : Susceptible

I : Intermediate

51 (52.0%)

PCG (N=98)

35 (35.7%)

CTX (N=84)

74 (88.1%)

MEPM (N=92)

78 (84.8%)

EM (N=81)

I:3 (3.7%)
11 (13.6%)

20 (29.9%)

CLDM (N=67)

R : Resistant
12 (12.2%)

I:9 (10.7%) R:1 (1.2%)

I:12 (13.0%)
2 (2.2%)67 (82.7%)

I:1 (1.5%)

46 (68.7%)

91 (100.0%)

LVFX (N=91)

0%

10%

20%

30%

40%

50%

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
90 (100.0%)

VCM (N=90)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.

15This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(CLSI2007)(Other than Cerebrospinal Fluid)†
S : Susceptible

I : Intermediate

14,300 (52.5%)

PCG (N=27,256)

9,617 (35.3%)3,339 (12.3%)

22,135 (95.8%)

CTX (N=23,096)

R : Resistant

I:506 (2.2%)

I:3,301 (13.2%)
1,279 (5.1%)

20,406 (81.7%)

MEPM (N=24,986)
I:617 (2.8%)
2,484 (11.1%)

EM (N=22,435)

8,241 (41.8%)

CLDM (N=19,719)

19,334 (86.2%)
I:409 (2.1%)

11,069 (56.1%)
I:161 (0.6%)794 (3.1%)

24,809 (96.3%)

LVFX (N=25,764)

0%

10%

20%

R:455 (2.0%)

30%

40%

50%

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
25,425 (100.0%)

VCM (N=25,425)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.

16
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(CLSI2009)(Cerebrospinal Fluid)†
S : Susceptible

I : Intermediate

51 (52.6%)

PCG (N=97)

46 (47.4%)

CTX (N=84)

74 (88.1%)

MEPM (N=92)

78 (84.8%)

EM (N=81)

I:3 (3.7%)
11 (13.6%)

20 (29.9%)

CLDM (N=67)

R : Resistant

I:9 (10.7%) R:1 (1.2%)

I:12 (13.0%)
2 (2.2%)67 (82.7%)

I:1 (1.5%)

46 (68.7%)

91 (100.0%)

LVFX (N=91)

0%

10%

20%

30%

40%

50%

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
90 (100.0%)

VCM (N=90)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2009 (M100-S19) criteria are excluded.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.

17This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(CLSI2009)(Other than Cerebrospinal Fluid)†
S : Susceptible

I : Intermediate

R : Resistant

PCG (N=26,932)

I:581 (2.2%)
26,223 (97.4%)

R:128 (0.5%)

22,135 (95.8%)

I:506 (2.2%)

R:455 (2.0%)

CTX (N=23,096)

I:3,301 (13.2%)
1,279 (5.1%)

20,406 (81.7%)

MEPM (N=24,986)
I:617 (2.8%)
2,484 (11.1%)

EM (N=22,435)

8,241 (41.8%)

CLDM (N=19,719)

19,334 (86.2%)
I:409 (2.1%)

11,069 (56.1%)
I:161 (0.6%)794 (3.1%)

24,809 (96.3%)

LVFX (N=25,764)

0%

10%

20%

30%

40%

50%

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
25,425 (100.0%)

VCM (N=25,425)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2009 (M100-S19) criteria are excluded.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.

18
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pyogenes†
S : Susceptible

I : Intermediate

R : ResistantI:15 (0.7%)
1,182 (55.1%)

EM (N=2,145)

948 (44.2%)

I:13 (0.6%)
1,658 (78.4%)

CLDM (N=2,116)

0%

10%

20%

30%

40%

50%

445 (21.0%)

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible

PCG (N=2,501)

2,501 (100.0%)

ABPC (N=2,545)

2,545 (100.0%)

NS:5 (0.2%)
CTX (N=2,105)

2,100 (99.8%)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. pyogenes corresponds to Isolated Bacterial Code 1111.

19This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus agalactiae†
S : Susceptible

I : Intermediate

R : Resistant

I:615 (3.5%)
11,905 (67.0%)

EM (N=17,779)

5,259 (29.6%)

I:316 (1.9%)
12,442 (75.9%)

CLDM (N=16,385)

0%

10%

20%

30%

40%

50%

3,627 (22.1%)

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
NS:1,214 (6.1%)

PCG (N=19,867)

18,653 (93.9%)

NS:334 (1.6%)
ABPC (N=20,756)

20,422 (98.4%)

NS:385 (3.0%)
CTX (N=12,844)

12,459 (97.0%)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. agalactiae corresponds to Isolated Bacterial Code 1114.

20This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Escherichia coli†
S : Susceptible

I : Intermediate
I:1,311 (0.9%)

75,092 (49.8%)

ABPC (N=150,867)

TAZ/PIPC (N=51,286)

74,464 (49.4%)

I:4,937 (3.2%)

84,515 (54.3%)

PIPC (N=155,626)

R : Resistant66,174 (42.5%)
I:882 (1.7%)
1,147 (2.2%)

49,257 (96.0%)

I:3,901 (2.4%)
43,462 (26.9%)

114,034 (70.7%)

CEZ (N=161,397)

I:1,899 (1.5%)
22,196 (17.8%)

100,378 (80.6%)

CTX (N=124,473)

I:6,221 (3.9%)
8,824 (5.5%)

CAZ (N=161,163)

146,118 (90.7%)

CFPM (N=81,456)

71,544 (87.8%)

I:1,015 (1.2%)
8,897 (10.9%)

AZT (N=126,777)

107,365 (84.7%)

I:6,526 (5.1%)
12,886 (10.2%)

IPM (N=146,007)

I:35 (0.0%)
145,889 (99.9%)

R:83 (0.1%)

MEPM (N=95,180)

I:33 (0.0%)
95,068 (99.9%)

R:79 (0.1%)

AMK (N=161,406)

I:417 (0.3%)
160,695 (99.6%)

R:294 (0.2%)

LVFX (N=155,998)

I:2,103 (1.3%)
55,384 (35.5%)

98,511 (63.1%)
0%

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†E. coli corresponds to Isolated Bacterial Codes 2001-2007.

21
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Klebsiella pneumoniae†
S : Susceptible
ABPC (N=80,030)

I : Intermediate

R : Resistant

S:3,763 (4.7%) I:14,006 (17.5%)
62,261 (77.8%)
I:16,306 (19.7%)
20,067 (24.3%)

46,235 (56.0%)

PIPC (N=82,608)
TAZ/PIPC (N=27,279)

I:345 (1.3%)
609 (2.2%)

26,325 (96.5%)

CEZ (N=85,320)

76,791 (90.0%)

I:740 (0.9%)
7,789 (9.1%)

CTX (N=66,654)

62,572 (93.9%)

I:652 (1.0%)
3,430 (5.1%)

CAZ (N=84,761)

81,773 (96.5%)

I:705 (0.8%)
2,283 (2.7%)

CFPM (N=41,143)

39,752 (96.6%)

I:168 (0.4%)
1,223 (3.0%)

AZT (N=67,253)

64,239 (95.5%)

I:679 (1.0%)
2,335 (3.5%)

IPM (N=77,193)

I:33 (0.0%)
77,067 (99.8%)

R:93 (0.1%)

MEPM (N=48,190)

I:40 (0.1%)
48,062 (99.7%)

R:88 (0.2%)

AMK (N=84,916)

I:130 (0.2%)
84,621 (99.7%)

R:165 (0.2%)

LVFX (N=83,063)

79,822 (96.1%)
0%

10%

20%

30%

40%

50%

60%

I:1,155 (1.4%)
2,086 (2.5%)
70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†K. pneumoniae corresponds to Isolated Bacterial Code 2351.

22This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterobacter cloacae†
S : Susceptible

I : Intermediate

R : Resistant

ABPC (N=35,849)

S:2,673 (7.5%) I:4,187 (11.7%)
28,989 (80.9%)

PIPC (N=36,988)

26,845 (72.6%)

TAZ/PIPC (N=11,895)
CEZ (N=37,359)

I:2,514 (6.8%)
7,629 (20.6%)
I:969 (8.1%)
1,230 (10.3%)

9,696 (81.5%)
S:794 (2.1%)

I:258 (0.7%)
36,307 (97.2%)

CTX (N=30,106)

21,908 (72.8%)

I:2,431 (8.1%)
5,767 (19.2%)

CAZ (N=37,202)

27,966 (75.2%)

I:1,586 (4.3%)
7,650 (20.6%)
I:276 (1.5%)758 (4.2%)

16,866 (94.2%)

CFPM (N=17,900)

I:1,916 (6.5%)
4,950 (16.8%)

22,594 (76.7%)

AZT (N=29,460)
IPM (N=34,403)

I:79 (0.2%)
34,192 (99.4%)

R:132 (0.4%)

MEPM (N=21,164)

I:81 (0.4%)
20,961 (99.0%)

R:122 (0.6%)

AMK (N=37,947)

I:93 (0.2%)
37,709 (99.4%)

R:145 (0.4%)

LVFX (N=37,274)

I:1,043 (2.8%)
1,573 (4.2%)

34,658 (93.0%)
0%

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†E. cloacae corresponds to Isolated Bacterial Code 2151.

23This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterobacter aerogenes†
S : Susceptible
ABPC (N=17,362)

S:1,671 (9.6%) I:2,406 (13.9%)

TAZ/PIPC (N=5,568)

R : Resistant13,285 (76.5%)
I:2,570 (14.3%)
2,617 (14.5%)

12,842 (71.2%)

PIPC (N=18,029)

CEZ (N=17,945)

I : Intermediate

I:695 (12.5%)350 (6.3%)

4,523 (81.2%)
S:1,324 (7.4%) I:333 (1.9%)
16,288 (90.8%)

CTX (N=14,452)

11,495 (79.5%)

I:2,204 (15.3%)
753 (5.2%)

CAZ (N=17,992)

13,797 (76.7%)

I:1,087 (6.0%)
3,108 (17.3%)
I:45 (0.5%)

8,773 (98.5%)

CFPM (N=8,909)

I:1,192 (8.1%)
1,105 (7.5%)

12,342 (84.3%)

AZT (N=14,639)

I:65 (0.4%)

R:71 (0.4%)

I:23 (0.2%)

R:24 (0.2%)

I:11 (0.1%)

R:45 (0.2%)

IPM (N=16,881)

16,745 (99.2%)

MEPM (N=10,249)

10,202 (99.5%)

AMK (N=18,369)

18,313 (99.7%)

LVFX (N=18,111)

I:105 (0.6%)
17,807 (98.3%)
0%

10%

20%

30%

40%

50%

R:91 (1.0%)

60%

70%

R:199 (1.1%)

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†E. aerogenes corresponds to Isolated Bacterial Code 2152.

24
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Citrobacter freundii†
S : Susceptible
3,056 (26.8%)

ABPC (N=11,397)

I : Intermediate

I:1,927 (16.9%)

6,414 (56.3%)
I:881 (7.5%)
2,557 (21.8%)

8,315 (70.7%)

PIPC (N=11,753)
TAZ/PIPC (N=4,309)
CEZ (N=12,044)

R : Resistant

I:337 (7.8%)
189 (4.4%)

3,783 (87.8%)
S:633 (5.3%)

I:255 (2.1%)

11,156 (92.6%)

CTX (N=9,746)

7,496 (76.9%)

I:1,368 (14.0%)882 (9.0%)

CAZ (N=11,942)

9,142 (76.6%)

I:328 (2.7%)
2,472 (20.7%)
I:46 (0.8%)

5,874 (97.9%)

CFPM (N=6,003)

I:741 (7.7%)
1,351 (14.1%)

7,503 (78.2%)

AZT (N=9,595)
IPM (N=10,754)

10,725 (99.7%)

MEPM (N=7,163)

7,136 (99.6%)

AMK (N=12,377)

12,332 (99.6%)

LVFX (N=11,831)

I:10 (0.1%)

R:19 (0.2%)

I:10 (0.1%)

R:17 (0.2%)

I:12 (0.1%)

R:33 (0.3%)
I:249 (2.1%)
360 (3.0%)

11,222 (94.9%)
0%

10%

20%

30%

40%

50%

R:83 (1.4%)

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†C. freundii corresponds to Isolated Bacterial Code 2051.

25
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Citrobacter koseri†
S : Susceptible
ABPC (N=5,081)

I : Intermediate

S:39 (0.8%) I:254 (5.0%)

1,400 (26.0%)

PIPC (N=5,380)

R : Resistant4,788 (94.2%)

2,128 (39.6%)

1,852 (34.4%)

I:42 (2.7%)
141 (8.9%)

1,399 (88.4%)

TAZ/PIPC (N=1,582)

CEZ (N=5,284)

4,226 (80.0%)

I:33 (0.6%)
1,025 (19.4%)

CTX (N=4,228)

3,498 (82.7%)

I:67 (1.6%)
663 (15.7%)

CAZ (N=5,384)

4,583 (85.1%)

I:220 (4.1%)
581 (10.8%)

AZT (N=4,242)

3,582 (84.4%)

I:69 (1.6%)
591 (13.9%)

IPM (N=4,908)

4,895 (99.7%)

MEPM (N=3,290)

3,283 (99.8%)

AMK (N=5,346)

5,320 (99.5%)

I:3 (0.1%)

R:10 (0.2%)

I:4 (0.1%)

R:3 (0.1%)

I:20 (0.4%)

R:6 (0.1%)

I:52 (1.0%)
850 (15.9%)

4,447 (83.1%)

LVFX (N=5,349)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†C. koseri corresponds to Isolated Bacterial Code 2052.

26
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Proteus mirabilis†
S : Susceptible

I : Intermediate

ABPC (N=14,283)

9,316 (65.2%)

PIPC (N=14,912)

10,412 (69.8%)

I:187 (1.3%)
4,780 (33.5%)
I:508 (3.4%)
3,992 (26.8%)

4,577 (99.4%)

TAZ/PIPC (N=4,605)

R : ResistantI:15 (0.3%)

I:345 (2.3%)
3,952 (26.4%)

10,697 (71.3%)

CEZ (N=14,994)

I:361 (3.2%)
1,950 (17.2%)

8,999 (79.6%)

CTX (N=11,310)

I:110 (0.7%)
14,915 (98.7%)

CAZ (N=15,113)

R:13 (0.3%)

R:88 (0.6%)

AZT (N=11,898)

10,852 (91.2%)

I:149 (1.3%)
897 (7.5%)

IPM (N=12,449)

11,305 (90.8%)

I:415 (3.3%)
729 (5.9%)
I:8 (0.1%)

MEPM (N=8,945)

8,928 (99.8%)

AMK (N=15,088)

I:107 (0.7%)
14,952 (99.1%)

0%

10%

20%

30%

40%

50%

R:29 (0.2%)

I:1,272 (8.5%)
2,337 (15.5%)

11,421 (76.0%)

LVFX (N=15,030)

R:9 (0.1%)

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†P. mirabilis corresponds to Isolated Bacterial Code 2201.

27
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Proteus vulgaris†
S : Susceptible
ABPC (N=3,561)

S:139 (3.9%)

I : Intermediate

I:31 (0.9%)

3,391 (95.2%)
I:661 (18.2%)
556 (15.3%)

2,421 (66.5%)

PIPC (N=3,638)

I:1 (0.1%)

1,202 (99.5%)

TAZ/PIPC (N=1,208)

CEZ (N=3,717)

R : Resistant

S:118 (3.2%)

I:40 (1.1%)

3,559 (95.7%)
I:254 (8.5%)
311 (10.4%)

2,428 (81.1%)

CTX (N=2,993)

I:21 (0.6%)

3,713 (98.3%)

CAZ (N=3,778)

2,879 (94.6%)

IPM (N=3,044)

I:112 (3.7%)

MEPM (N=2,050)

2,047 (99.9%)

AMK (N=3,781)

3,763 (99.5%)

LVFX (N=3,716)

3,668 (98.7%)

0%

10%

20%

30%

40%

50%

R:44 (1.2%)

I:52 (1.7%)
382 (12.7%)

2,585 (85.6%)

AZT (N=3,019)

R:5 (0.4%)

R:53 (1.7%)

I:2 (0.1%)

R:1 (0.0%)

I:5 (0.1%)

R:13 (0.3%)

I:21 (0.6%)

R:27 (0.7%)

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†P. vulgaris corresponds to Isolated Bacterial Code 2202.

28
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Serratia marcescens†
S : Susceptible

I : Intermediate

R : Resistant

ABPC (N=20,802)

S:1,033 (5.0%) I:2,369 (11.4%)
17,400 (83.6%)

PIPC (N=21,735)

15,849 (72.9%)

TAZ/PIPC (N=6,770)
CEZ (N=21,365)

I:3,572 (16.4%)
2,314 (10.6%)
I:797 (11.8%)359 (5.3%)

5,614 (82.9%)
S:20 (0.1%) I:20 (0.1%)

21,325 (99.8%)
I:2,256 (13.6%)
1,843 (11.1%)

12,442 (75.2%)

CTX (N=16,541)
CAZ (N=21,885)

I:594 (2.7%)
2,503 (11.4%)

18,788 (85.8%)

I:76 (0.7%)
10,644 (98.1%)

CFPM (N=10,846)

I:831 (4.7%)
1,219 (6.9%)

15,565 (88.4%)

AZT (N=17,615)

I:70 (0.3%)

R:56 (0.3%)

I:18 (0.1%)

R:20 (0.2%)

I:225 (1.0%)
21,782 (98.5%)

R:99 (0.4%)

IPM (N=20,149)

20,023 (99.4%)

MEPM (N=12,517)

12,479 (99.7%)

AMK (N=22,106)
LVFX (N=21,967)

I:926 (4.2%)
880 (4.0%)

20,161 (91.8%)
0%

10%

20%

30%

R:126 (1.2%)

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†S. marcescens corresponds to Isolated Bacterial Code 2101.

29
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Pseudomonas aeruginosa†
S : Susceptible

I : Intermediate

R : Resistant

PIPC (N=122,581)

108,557 (88.6%)

14,024 (11.4%)

TAZ/PIPC (N=68,686)

62,473 (91.0%)

6,213 (9.0%)
I:7,041 (5.6%)
12,720 (10.2%)

105,103 (84.2%)

CAZ (N=124,864)

I:16,788 (15.9%)
17,451 (16.5%)

71,442 (67.6%)

AZT (N=105,681)

CFPM (N=106,291)

IPM (N=119,979)

MEPM (N=119,330)

GM (N=118,592)

86,917 (81.8%)

I:10,863 (10.2%)
8,511 (8.0%)

93,966 (78.3%)

I:5,535 (4.6%)
20,478 (17.1%)

100,208 (84.0%)

I:6,369 (5.3%)
12,753 (10.7%)

99,570 (84.0%)

I:12,789 (10.8%)
6,233 (5.3%)
I:3,946 (3.1%)
2,608 (2.1%)

119,469 (94.8%)

AMK (N=126,023)

I:8,181 (6.9%)
17,298 (14.5%)

93,683 (78.6%)

LVFX (N=119,162)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†P. aeruginosa corresponds to Isolated Bacterial Code 4001.

30This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Acinetobacter spp.†
S : Susceptible
PIPC (N=20,183)

I : Intermediate

R : ResistantI:3,397 (16.8%)
2,611 (12.9%)

14,175 (70.2%)

I:245 (4.9%)384 (7.8%)

4,324 (87.3%)

TAZ/PIPC (N=4,953)

I:119 (2.6%)
263 (5.8%)

4,116 (91.5%)

SBT/ABPC (N=4,498)

CAZ (N=20,856)

17,562 (84.2%)

I:1,202 (5.8%)
2,092 (10.0%)

CFPM (N=15,394)

12,994 (84.4%)

I:983 (6.4%)
1,417 (9.2%)

IPM (N=16,947)

16,343 (96.4%)

I:217 (1.3%)
387 (2.3%)

MEPM (N=17,027)

16,392 (96.3%)

I:244 (1.4%)
391 (2.3%)
I:515 (2.7%)
1,851 (9.5%)

17,056 (87.8%)

GM (N=19,422)

I:155 (0.7%)724 (3.5%)

19,984 (95.8%)

AMK (N=20,863)

LVFX (N=20,040)

I:1,132 (5.6%)
1,658 (8.3%)

17,250 (86.1%)

14,513 (90.3%)

ST (N=16,068)

0%

10%

20%

30%

40%

50%

1,555 (9.7%)

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†Acinetobacter spp. correspond to Isolated Bacterial Codes 4400-4403.

31This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Haemophilus influenzae†
S : Susceptible
ABPC (N=26,604)

I : Intermediate
5,735 (21.6%)

11,874 (44.6%)

R : Resistant
8,995 (33.8%)

15,750 (72.9%)

SBT/ABPC (N=21,606)
CVA/AMPC (N=14,235)

5,856 (27.1%)

11,693 (82.1%)

CAM (N=22,286)

2,542 (17.9%)
I:4,438 (19.9%)
1,009 (4.5%)

16,839 (75.6%)

I:45 (0.4%)
11,194 (98.3%)

R:153 (1.3%)

40%

80%

TC (N=11,392)
0%

10%

20%

30%

50%

S : Susceptible

60%

70%

90% 100%

NS : Non-susceptible
NS:283 (1.4%)

CTX (N=20,034)

19,751 (98.6%)

NS:985 (3.9%)
MEPM (N=25,235)

24,250 (96.1%)

NS:470 (1.9%)
LVFX (N=24,864)

24,394 (98.1%)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
†H. influenzae corresponds to Isolated Bacterial Codes 3201, 3202, 3203, 3205, 3208, 3211, 3214, 3217, 3220 and 3223.

32This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

Annual Open Report 2013
Japan Nosocomial Infections Surveillance (JANIS)Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Penicillin-resistant Streptococcus pneumoniae (PRSP)(Outpatient)†
S : Susceptible
S:1 (0.0%)

PCG (N=18,727)

I : Intermediate

R : Resistant14,188 (75.8%)

4,538 (24.2%)
I:632 (4.3%)
450 (3.1%)

13,650 (92.7%)

CTX (N=14,732)

R:1,500 (8.8%)
4,388 (25.7%)

11,177 (65.5%)

MEPM (N=17,065)
S:975 (6.6%)

EM (N=14,822)

CLDM (N=12,012)

I:341 (2.3%)

4,864 (40.5%)

13,506 (91.1%)

I:291 (2.4%)

LVFX (N=17,294)

6,857 (57.1%)
I:165 (1.0%)456 (2.6%)

16,673 (96.4%)

0%

10%

20%

30%

40%

50%

60%

S : Susceptible

70%

80%

90%

100%

NS : Non-susceptible
15,650 (100.0%)

VCM (N=15,650)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Outpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Uninterpretable results according to the CLSI 2007 (M100-S17) criteria are excluded.
† Penicillin-resistantStreptococcus pneumoniae (PRSP) corresponds to Isolated Bacterial code 1131 ʻIntermediateʼ, ʻIntermediate
or Resistantʼ and ʻResistantʼ to Antimicrobial Code 1201 (Benzylpenicillin).

33
This Open Report does not cover every data from facilities nationwide.
Date of Tabulation :May 09, 2014

Date of Publication (English version) :January 12, 2016

【Appendix 1
Isolated
Bacterium
Methicillin-Resistant
Staphylococcus aureus(MRSA)
VancomycinResistant
Staphylococcus aureus(VRSA)
VancomycinResistant Enterococci(VRE)

Penicillin-Resistant
Streptococcus
pneumoniae(PRSP)
Multidrug-ResistantPseudomonas
aeruginosa(MDRP)

Multidrug-ResistantAcinetobacter spp.
(MDRA)¶

CarbapenemResistantPseudomonas
aeruginosa

Interpretive Criteria for Specific AMR Bacteria based on the Broth Microdilution Method】
Comments*
S. aureus resistant to oxacillin by thebroth microdilution method or
methicillin-resistant S. aureus detected
on selective media
S. aureus resistant to vancomycin

Enterococcus spp. resistant† tovancomycin by the broth microdilution
method or vancomycin-resistantenterococci detected on selective media
Note: Excluding species that were not
identified within Enterococcus sp.
S. pneumoniae resistant† topenicillin G

P. aeruginosa satisfying all of thefollowing criteria:
1. Resistant† to carbapenems(imipenem and/or meropenem)
2. Resistant† to aminoglycosides(amikacin)
3. Resistant to fluoroquinolones (any ofnorfloxacin, ofloxacin, levofloxacin,
ciprofloxacin, lomefloxacin, andgatifloxacin).
Acinetobacter spp. satisfying all of thefollowing criteria:
1. Resistant to carbapenems (imipenem
and/or meropenem)
2. Resistant† to aminoglycosides(amikacin)
3. Resistant to fluoroquinolones (any oflevofloxacin, ciprofloxacin, andgatifloxacin).
P. aeruginosa resistant to imipenem
and/or meropenem

MIC Values by BrothMicrodilution Method
oxacillin ≥ 4 μg/ml

Isolated Bacterial
Code Ver.4.0
1301, 1303

vancomycin ≥ 16 μg/ml

1301,1303–1306

vancomycin ≥ 16 μg/ml†

1201,1202,1205,
1206,1209,1210,
1213–1217

penicillin G ≥ 0.125 μg/ml†

Isolated
Bacterium
CarbapenemResistantSerratia marcescens
3rd Generation
CephalosporinResistant Klebsiellapneumoniae
3rd Generation
CephalosporinResistantEscherichia coli
FluoroquinoloneResistantEscherichia coli

Serratia marcescens resistant toimipenem and/or meropenem

MIC Values by BrothMicrodilution Method
imipenem ≥ 16 μg/ml,
meropenem ≥ 16 μg/ml

K. pneumoniae resistant to cefotaxime
and/or ceftazidime

cefotaxime ≥ 16 μg/ml,
ceftazidime ≥ 32 μg/ml

2351

E. coli resistant to cefotaxime and/or
ceftazidime

cefotaxime ≥ 16 μg/ml,
ceftazidime ≥ 32 μg/ml

2001–2007

E. coli resistant to fluoroquinolones (anyof norfloxacin, ofloxacin, levofloxacin,
lomefloxacin, gatifloxacin, andciprofloxacin)

norfloxacin ≥ 16 μg/ml,
ofloxacin ≥ 8 μg/ml,
levofloxacin ≥ 8 μg/ml,
lomefloxacin ≥ 8 μg/ml,
gatifloxacin ≥ 8 μg/ml,
ciprofloxacin ≥ 4 μg/ml

2001–2007

Comments*

1131

1. imipenem ≥ 16 μg/ml,
meropenem ≥ 16 μg/ml
2. amikacin ≥ 32 μg/ml†
3. norfloxacin ≥ 16 μg/ml,
ofloxacin ≥ 8 μg/ml,
levofloxacin ≥ 8 μg/ml,
lomefloxacin≥ 8 μg/ml,
gatifloxacin ≥ 8 μg/ml,
ciprofloxacin ≥ 4 μg/ml

4001

1. imipenem ≥ 16 μg/ml,
meropenem ≥ 16 μg/ml
2. amikacin ≥ 32 μg/ml†
3. levofloxacin ≥ 8 μg/ml,
ciprofloxacin ≥ 4 μg/ml,
gatifloxacin ≥ 8 μg/ml

4400–4403

imipenem ≥ 16 μg/ml,
meropenem ≥ 16 μg/ml

4001* In principle, RIS interpretation is based on the CLSI2007 (M100-S10) guidelines† Criteria are based on the Infectious Diseases Control Law¶Following modification was applied for Multidrug-resistant Acinetobacter spp.;
Interpretive Criteria(Satisfy all three criteria listed below)① imipenem ≥ 16 μg/ml or
meropenem ≥ 16 μg/ml② amikacin ≥ 64 μg/ml③ levofloxacin ≥ 8 μg/ml or
ciprofloxacin ≥ 4 μg/ml① imipenem ≥ 16 μg/ml or
meropenem ≥ 16 μg/ml② amikacin ≥ 32 μg/ml③ levofloxacin ≥ 8 μg/ml,
ciprofloxacin ≥ 4 μg/ml or
gatifloxacin ≥ 8 μg/ml

Tabulation Period
Quarterly Feedback Report
From Jul-Sep, 2007 to Oct-Dec, 2010
Annual Feedback Report
From 2007 to 2009
Quarterly Feedback Report
From Jan-Mar, 2011 to present
Annual Feedback Report
From 2010 to present

Isolated Bacterial
Code Ver.4.0
2101

【Appendix 2

Method to Eliminate Duplicates of Annual Report】

1. Rule of Counting Days
“Day 1” is defined as the day after the "Specimen Reception Date". For example, if
a specimen is received on March 1, “Day 1” will be March 2 and “Day 30” will be
March 31.
wi thin 30 days
Example)Ma rchApri lMar 31"Da y 30"

Mar 2
"Da y 1"
Mar 1
"Specimen
Reception Date"

Example)28 daysSpecimen
Reception Date

2. Number of "Specimen-submitting Patients"
The number of “Specimen-submitting Patients” is equal to the number of
inpatients whose specimens were submitted, regardless of the specimen sources.
If more than one specimen is submitted by one patient within 30 days, thenumber of “Specimen-submitting Patients” is defined as one. This is how weeliminate duplicates.
Example)Speci men
Receiption Date

3. Number of Patients with Major/Specific AMR Bacteria
The same method used to eliminate duplicate “Specimen-submitting Patients”
records is applied to “Patients with Major/Specific AMR Bacteria”. If more than one
identical bacterium is isolated from the same patient within 30 days, the numberof “Patients with Major/Specific AMR Bacteria” is not recounted.
To obtain the number of “Patients with Specific AMR Bacteria”, first the data
regarding pathogens which meet “Specific AMR Bacteria” criteria are extracted.
Then the method mentioned above is applied to eliminate duplicates.

Ma rchMar 2Apri lMar 30Speci men
Speci mens ubmitting
Pa ti ents

The number of "Specimen-submitting
Pa ti ents" is not recounted i f thes econd specimen is s ubmitted within
30 da ysApr 10

Ma y

Mar 2

35 days

39 days

Ma rchApri lMar 30

Apr 10

Ma y
May 15Specimen
Pts with Major/
Specific AMR
bacteria

The number of "Pa tients with
Ma jor/Specific AMR Ba cteria" is notrecounted i f an i solated pathogen is
the s ame species as one identified
wi thin the past 30 da ys

The number of "Pa tiens with
Ma jor/Specific AMR Ba cteria" isrecounted i f the same pathogen i s
i s olated again on or a fter 31 da ys

May 15

4. Definition of Isolates Based on the Results of Antimicrobial Susceptibility Testing(AST)
If the AST results differ* between the same bacteria isolated within 30 days, eachof them is counted separately.
*Difference of AST is determined by satisfying any of the following four criteria:① More than four-fold difference in the MIC value; however,
MIC > 2 is equivalent to MIC ≥ 4 and is interpreted as MIC = 4, andThe number of "Specimen-submitting
MIC < 16 is equivalent to MIC ≤ 16 and is interpreted as MIC = 16
② Findings of “R and S” on RIS interpretation
Pa ti ents" is recounted if the second③ Findings of “- and ++”, “+ and +++”, or “- and +++” on +/- interpretations pecimen is submitted on after 31④
Fewer than five duplicate antimicrobial agents among testingsda ys

【Appendix 2

Method to Eliminate Duplicates of Annual Report】

5. Method for Eliminating Duplicates Based on the Results of AST-

The following method will be applied to eliminate duplicates if “Identical Bacteria”
are detected more than once from the same patient within 30 days, according to
the criteria in Section 4.
With regard to the “Specimen Reception Date”, whichever is the earliest will be
adoptedData in which the greatest number of antimicrobial agents tested will be adopted
as the “Results of AST”
Adopted Specimen
Reception Date

Adopted Resultof AST

Example 1

Number of Antimicrobial Agents Tested: SEVEN on March 1 and ONE on March 31

Mar 1Within 30 days

Mar 31

SEVEN

March 1

SEVEN

ONE

Example 2

Number of Antimicrobial Agents Tested: TWO on March 1 and FIVE on March 31

Mar 1


TWO

Within 30 days

Mar 31March 1FIVE
FIVE

【Appendix 3

Box Plot Chart】

1. Box Plot Chart
The chart represents the data distribution of the facilities.

2.

Box Plot Chart of Feedback Reports

ExampleExampleMinimum: 1.40%, Median: 8.58%, Maximum: 40.66%
1.40

40.66

8.58

7.33

※

Percentile represents the position of a single data value within a group of
samples in ascending order. For example, if a group contains 100 samples,
then the 10th percentile refers to the position of the 10th smallest value inthe group.

(252cases)(466.4 cases)

186 cases(14.65%)

114,933 cases 1.40 8.58
(8.77%)

0 cases(0.00%)

0 cases 0.00
(0.00%)

0 cases(0.00%)

407 cases 0.00 0.00
(0.03%)

40.66

3.76